TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04302285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKU type meal and Exercise
Description: * Exercise was conducted prior to PKU type meal.~* PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKU type meal
Description: PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
Study: NCT00266812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy
Description: Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiotherapy
Description: 2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
Study: NCT02786667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months treatment with Placebo up to 8 mg per day with a titration period for one month
Study: NCT04656119

Intervention type: OTHER
Intervention: there is no intervention in our study
Description: there is no intervention in our study

Intervention type: OTHER
Intervention: there is no intervention in our study
Description: there is no intervention in our study
Study: NCT03142100

Intervention type: DEVICE
Intervention: cochlear implants and hearing aids
Description: speech perception tests and bimodal fitting

Intervention type: DEVICE
Intervention: cochlear implants and hearing aids
Description: speech perception tests and bimodal fitting
Study: NCT02506036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain HQ
Description: Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain HQ
Description: Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
Study: NCT01719302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
Study: NCT03427281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
Study: NCT00005585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
Study: NCT00561353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
Study: NCT00005585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT02716285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ileocolonic release peppermint oil
Description: Peppermint oil, menthae piperitae aetheroleum
Study: NCT00561353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
Study: NCT03942445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrocnemius muscle biopsy
Description: In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrocnemius muscle biopsy
Description: In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
Study: NCT02716285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, containing microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small intestinal release peppermint oil
Description: Peppermint oil, menthae piperitae aetheroleum
Study: NCT01051804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra
Description: Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive lubricant Eye Drops
Description: Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
Study: NCT04215770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day
Description: Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day
Description: Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
Study: NCT02328729

Intervention type: PROCEDURE
Intervention: mandibular block with Epinephrine
Description: Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine

Intervention type: PROCEDURE
Intervention: C-CLAD-IL with Epinephrine
Description: Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine

Intervention type: PROCEDURE
Intervention: Infiltration with Epinephrine
Description: Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine

Intervention type: PROCEDURE
Intervention: Mandibular block without Epinephrine
Description: Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine

Intervention type: PROCEDURE
Intervention: C-CLAD-IL without Epinephrine
Description: Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine

Intervention type: PROCEDURE
Intervention: nfiltration without Epinephrine
Description: Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
Study: NCT01800760

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics once a day for three weeks.
Study: NCT03693898

Intervention type: OTHER
Group type: OTHER
Intervention: Observeational
Description: No intervention, observational
Study: NCT04127929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of cavities using glass carbomer material (GCP Dental)
Description: Detection of caries then restoration of cavities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)
Description: Detection of caries then restoration of cavities
Study: NCT02004171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic cigarette
Description: V2 Cigs with 24 mg nicotine cartridges

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine inhaler
Description: nicotine inhaler with 10 mg nicotine cartridges
Study: NCT03017664

Intervention type: OTHER
Intervention: Peptide-based enteral formula
Description: Peptide-based, higher protein and higher calorie enteral formula

Intervention type: OTHER
Intervention: Retrospective review of enteral tube feeding formula
Description: Enteral formula tube feeding will be retrospectively reviewed
Study: NCT02569983

Intervention type: OTHER
Intervention: Observational cohort
Description: No intervention - observational study
Study: NCT01779362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Titrated to 1000 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Titrated to 1000 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Titrated to 1000 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Titrated to 1.8 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Titrated to target fasting glucose \<90 mg/dl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching to metformin 1000 mg BI
Study: NCT02353663

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography examination
Study: NCT01718691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: A dose of 90 mg/m\^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: A dose of 375 mg/m\^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
Study: NCT02502500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Study: NCT00673829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells and Interleukin 2
Description: One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
Study: NCT03512886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-task training
Description: In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single task training
Description: An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
Study: NCT03974958

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tissue-library
Description: circulating biomarkers (miRNA panel) analysis of blood samples

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Tissue-library
Description: circulating biomarkers (miRNA panel) analysis of blood samples
Study: NCT03380572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senhance Assisted Cholecystectomy
Description: Cholecystectomy performed using Senhance surgical robotic system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Description: Standard laparoscopic cholecystectomy
Study: NCT00354211

Intervention type: DEVICE
Intervention: minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)
Study: NCT02210195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: 125 mg daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
Study: NCT01184807

Intervention type: DRUG
Group type: OTHER
Intervention: OPB-51602
Description: OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
Study: NCT04337073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
Study: NCT01200355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole
Description: Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Study: NCT02331407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic arm therapy
Description: Training with the ReoGo device